Skip to main content
New GLP-1 protocol guide just published Read →

GH Releasing Peptides: Structure and Kinetics

Bowers CY

Journal of Animal Science/1993

Background

Growth hormone-releasing peptides (GHRPs) are a family of synthetic hexapeptides discovered through systematic SAR studies aimed at understanding how to stimulate pituitary GH release through non-GHRH pathways. GHRP-2 emerged as one of the most potent members of this family.

Unlike growth hormone-releasing hormone (GHRH), which acts through a specific GHRH receptor on somatotroph cells, GHRPs act through a distinct receptor — later identified as the ghrelin receptor (GHS-R1a) — offering complementary and synergistic GH release when used with GHRH analogs.

Key Findings

  • GHRP-2 stimulates GH release with high potency in both in vitro pituitary cultures and in vivo animal models
  • Acts through a receptor that is pharmacologically distinct from the GHRH receptor
  • The combination of GHRP-2 + GHRH produces synergistic (supra-additive) GH release exceeding either agent alone
  • GHRP-2 also weakly stimulates ACTH and cortisol release — a distinguishing feature compared to the more GH-selective ipamorelin
  • GH pulse amplitude is amplified without significantly changing pulse frequency

Pharmacological Profile

ParameterGHRP-2
StructureHis-D-Trp-Ala-Trp-D-Phe-Lys-NH₂
RouteSC, IV, intranasal
Half-life~15–30 min
ReceptorGHS-R1a (ghrelin receptor)
SelectivityGH >> prolactin > ACTH/cortisol

Clinical Significance

This foundational review established the mechanistic framework for GHRPs as a class, defining GHRP-2’s pharmacology and distinguishing its mechanism from GHRH. The synergistic activity with GHRH became the basis for combination protocols (e.g., CJC-1295 + GHRP-2) widely used in research and clinical settings.

Understanding the GHS-R1a receptor mechanism also led to the discovery of ghrelin (2000), the endogenous GHRP-2 analog, which retroactively validated the receptor target that GHRP-2 had been developed against.

Limitations

  • Animal and in vitro data; human pharmacodynamics were characterized in subsequent human trials
  • Long-term effects on the GH/IGF-1 axis not addressed in this early review

Compounds Studied

Related Conditions

Related Studies